Q3 2022 BioArctic AB Earnings Call Transcript
Good morning, and welcome to the BioArctic Q3 Report 2022. (Operator Instructions) Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson, speakers. Please go ahead.
()-
Thank you so much. Good morning, and welcome to BioArctic's presentation from the third quarter. I'm Gunilla Osswald, I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson.
I will start by giving an update on BioArctic, and I will also focus, of course, on the fantastic news that we have had with lecanemab, with the groundbreaking results from the Clarity AD, the Phase III study in early Alzheimer's disease patients. It was great to see some robust and consistent results in the Phase III study. And of course, I will talk more about that here today.
So next slide, please. This is our disclaimer. Next slide, please. I'll start with a short introduction to BioArctic. I think BioArctic is a unique Swedish biopharma company, focusing on improving the lives
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |